Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYCHLOROQUINE SULFATE versus KRINTAFEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYCHLOROQUINE SULFATE versus KRINTAFEL.
HYDROXYCHLOROQUINE SULFATE vs KRINTAFEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antimalarial and immunosuppressive agent. Accumulates in lysosomes, raising pH, impairing antigen processing and presentation. Inhibits toll-like receptor signaling and cytokine production (e.g., IL-6, TNF-α). Interferes with quinone reductase activity and heme polymerization in plasmodia.
KRINTAFEL (tafenoquine) is an 8-aminoquinoline antimalarial that inhibits parasite growth by interfering with the electron transport chain in the mitochondria of Plasmodium species. It is active against both the erythrocytic and exoerythrocytic stages, including hypnozoites of P. vivax.
200-400 mg orally once daily or divided twice daily; maximum 600 mg/day or 6.5 mg/kg/day (whichever is lower). For malaria: 800 mg loading dose, then 400 mg at 6, 24, and 48 hours.
Adults: 200 mg orally as a single dose.
None Documented
None Documented
Terminal half-life: ~40–50 days (range 30–60 days) due to extensive tissue distribution. Steady-state reached after 4–6 months.
Terminal elimination half-life is approximately 5-7 days in healthy subjects. Due to accumulation, steady state is achieved after 4-5 weeks of weekly dosing. In patients with renal impairment, half-life may be prolonged.
Renal: ~50% unchanged; Hepatic metabolism: ~50% (desethylchloroquine, desethylhydroxychloroquine); Fecal: minimal (<5%).
Primarily renal; approximately 70-80% of administered dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Fecal excretion accounts for less than 5%.
Category A/B
Category C
Antimalarial / DMARD
Antimalarial